Adrox CV is indicated for the treatment of infections caused by sensitive bacteria. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis (beta-lactamase producing strains) or Streptococcus pyogenes. ... Read more Adrox CV is indicated for the treatment of infections caused by sensitive bacteria. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis (beta-lactamase producing strains) or Streptococcus pyogenes. Acute bacterial maxillary sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non beta-lactamase producing strains) Lower respiratory tract infections including pneumoniae, caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta lactamase-producing strains), Klebsiella spp., Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes, E. coli. Acute bacterial exacerbation of chronic bronchitis and secondary bacterial infections of Acute bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae (beta-lactamase negative strains) or Haemophilus parainfluenzae (beta-lactamase negative strains). Uncomplicated skin and skin-structure infections caused by Staphylococcus aureus (including beta-lactamase producing strains) or Streptococcus pyogenes. Uncomplicated urinary tract infections caused by E.coli or Klebsiella pneumoniae. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains). Uncomplicated Gonorrhoea caused by penicillinase-producing and non-penicillinase producing strains of Neisseria gonorrhoeae. Early Lyme Disease (erythema migrans) caused by Borrelia burgdorferi. Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, E.coli, Haemophilus influenzae (including ampicillin-resistant strains) & Klebsiella spp. Meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Neisseria meningitidis & Staphylococcus aureus (penicillinase and non-penicillinase producing strains) Switch therapy (Injectable to oral)
Always consult a registered doctor before taking any medicine. This information is for general knowledge only.
Cefuroxime is a bactericidal second generation cephalosporin antibiotic which is active against a wide range of Gram-positive and Gram-negative susceptible organisms including many beta-lactamase producing strains. Cefuroxime inhibits bacterial cell wall synthesis by interfering with the transpeptidation process. Clavulanic acid is a naturally derived beta lactamase inhibitor produced by Streptomyces clavuligerus. It has similar structure to beta lactam antibiotics which binds irreversibly to beta-lactamase enzymes and inactivates them. Clavulanic acid gives protection of Cefuroxime from degradation by beta lactamase enzymes and provides a solution for the treatment of bacterial infections caused by beta lactam resistant bacteria.
Adolescents and adults (13 years and older)- Pharyngitis/tonsillitis : 250 mg b.i.d. for 5-10 days Acute bacterial maxillary sinusitis : 250 mg b.i.d. for 10 days Acute bacterial exacerbation of chronic bronchitis : 250-500 mg b.i.d. for 10 days Secondary bacterial infections of acute bronchitis : 250-500 mg b.i.d. for 5-10 days Uncomplicated skin and skin structure infections : 250-500 mg b.i.d. for 10 days Uncomplicated urinary tract infections : 250 mg b.i.d. for 7-10 days Uncomplicated Gonorrhoea : 1000 mg b.i.d. Single dose Community acquired pneumonia : 250-500 mg b.i.d. for 5-10 days MDR Typhoid Fever : 500 mg b.i.d. for 10-14 days Early Lyme disease : 500 mg b.i.d. for 20 days Paediatric Patients (3 months to 12 years)- Pharyngitis/Tonsillitis : 20 mg/kg/day b.i.d for 5-10 days Acute otitis media : 30 mg/kg/day b.i.d for 10 days Acute bacterial maxillary sinusitis : 30 mg/kg/day b.i.d for 10 days Impetigo : 30 mg/kg/day b.i.d for 10 days Cefuroxime-Clavulanic Acid tablet may be taken without regard of food.
Generally Cefuroxime-Clavulanic Acid is well tolerated. However, a few side effects like nausea, vomiting, diarrhea, abdominal discomfort or pain may occur. As with other broad-spectrum antibiotics, prolonged administration of Cefuroxime and Clavulanic acid combination may result in overgrowth of nonsusceptible microorganisms. Rarely (<0.2%) renal dysfunction, anaphylaxis, angioedema, pruritis, rash and serum sickness like urticaria may appear.
Cefuroxime-Clavulanic Acid is contraindicated in patients with known allergy to cephalosporin & in patients with Pseudomembranous Colitis.
Concomitant administration of probenecid with Cefuroxime-Clavulanic Acid increases the area under the serum concentration versus time curve by 50%. Drug that reduces gastric acidity may result in a lower bioavailability of Cefuroxime and tend to cancel the effect of postprandial absorption.
Cefuroxime should be given with care to patients receiving concurrent treatment with potent diuretics & who has history of colitis.